Primary non-small cell lung cancer response upon treatment with denosumab.
Here we report the case of a patient with metastatic adenocarcinoma of the lung harboring an ALK gene translocation. In this patient a response of the primary tumor and metastases has been detected upon treatment with denosumab. A possible link between ALK and RANK is postulated.
Department of Oncology, University Hospital Zurich, Zurich, Switzerland. Electronic address: alessandra.curioni@usz.ch.
A
A
Curioni-Fontecedro
L
L
Husmann
D
D
Soldini
R A
RA
Stahel
D000077548:Anaplastic Lymphoma Kinase; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D001999:Bronchoscopy; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy*; D003371:Cough; D004252:DNA Mutational Analysis; D000069448:Denosumab; D018773:Genes, erbB-1 / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D053245:RANK Ligand / Q000276:immunology / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D012074:Remission Induction; D014057:Tomography, X-Ray Computed
D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
ALK; Crizotinib; Denosumab; NF-kB; Non small cell lung cancer; RANK; RANKL